Similar articles

• The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.

  Puri R, Nissen SE, Shao M, Kataoka Y, Uno K, Kapadia SR, Tuzcu EM, Nicholls SJ. Puri R, et al. Eur J Prev Cardiol. 2016 Mar;23(5):474-85. doi: 10.1177/2047487315572920. Epub 2015 Feb 17. Eur J Prev Cardiol. 2016. PMID: 25691546
• Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.

  Nakamura T, Obata JE, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, Watanabe K, Watanabe Y, Mishina H, Kugiyama K. Nakamura T, et al. Atherosclerosis. 2011 Sep;218(1):163-7. doi: 10.1016/j.atherosclerosis.2011.04.040. Epub 2011 May 6. Atherosclerosis. 2011. PMID: 21605862
• S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease.

  Saito T, Hojo Y, Ogoyama Y, Hirose M, Ikemoto T, Katsuki T, Shimada K, Kario K. Saito T, et al. Circ J. 2012;76(11):2647-52. doi: 10.1253/circj.cj-12-0093. Epub 2012 Jul 7. Circ J. 2012. PMID: 22786469 Clinical Trial.
• C-reactive protein as a risk factor versus risk marker.

  de Maat MP, Trion A. de Maat MP, et al. Curr Opin Lipidol. 2004 Dec;15(6):651-7. doi: 10.1097/00041433-200412000-00005. Curr Opin Lipidol. 2004. PMID: 15529024 Review.
• Ambient particulate matter, C-reactive protein, and coronary artery disease.

  Sandhu RS, Petroni DH, George WJ. Sandhu RS, et al. Inhal Toxicol. 2005 Jun-Jul;17(7-8):409-13. doi: 10.1080/08958370590929538. Inhal Toxicol. 2005. PMID: 16020037 Review.